¼¼°èÀÇ ÀÓ»ó¿ë Â÷¼¼´ë ½ÃÄö½Ì(NGS) ºÐ¾ß ºÐ¼®(2024-2030³â)
Analysis of the Clinical Next-generation Sequencing Sector, Global, 2024-2030
»óǰÄÚµå : 1606585
¸®¼­Ä¡»ç : Frost & Sullivan
¹ßÇàÀÏ : 2024³â 11¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 71 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,950 £Ü 6,814,000
Web Access (Regional License) help
Frost & SullivanÀÇ À¥»çÀÌÆ® ·Î±×ÀÎ ÆÐ½º¿öµå°¡ ¹ßÇàµÇ¸ç, PDF¸¦ ´Ù¿î·Îµå ¹Þ´Â ÇüÅ·ΠÁ¦°øµÉ ¿¹Á¤ÀÔ´Ï´Ù. PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ ¸ðµç ºÐµéÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù


Çѱ۸ñÂ÷

AI¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ÅõÀÚ·Î Á¤º¸ ¼Ö·ç¼Ç °³¹ß °¡¼ÓÈ­ ¹× Çõ½ÅÀû ¼ºÀå ÃËÁø

ÀÌ Frost & Sullivan ºÐ¼® º¸°í¼­´Â ÀÓ»ó¿ë Â÷¼¼´ë ½ÃÄö½Ì(NGS) »ê¾÷À» Á¶»çÇÏ¿© ´Ù¾çÇÑ À¯ÇüÀÇ Á¦Ç°, ¿öÅ©ÇÃ·Î¿ì ¹× ÀÓ»ó ¸ñÀûÀÇ ÀÀ¿ë ºÐ¾ß¸¦ Æ÷°ýÇÕ´Ï´Ù. NGS ½ÃÀåÀº 2024-2030³â µ¿¾È ¼­ºñ½º ¹× ÀÎÆ÷¸Åƽ½º ºÎ¹®ÀÌ ÁÖ¿ä ¿øµ¿·ÂÀ¸·Î ÀÛ¿ëÇØ ¾ÈÁ¤ÀûÀÎ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, NGS ½ÃÀå¿¡´Â Á¦¾à, »ý¸í°øÇÐ, Áø´Ü µî ÁÖ¿ä ÃÖÁ¾»ç¿ëÀÚ ºÎ¹®ÀÇ ÀÓ»óÀû ¿ëµµ¸¦ À§ÇÑ ´Ù¾çÇÑ À¯ÇüÀÇ Á¦Ç° ¹× ¿öÅ©Ç÷ο찡 Æ÷ÇԵ˴ϴÙ. ¶óÀ̺귯¸® Áغñ, ½ÃÄö½Ì, µ¥ÀÌÅÍ ºÐ¼® ¹× ÇØ¼®À» Æ÷ÇÔÇÑ ¿£µå-Åõ-¿£µå ¿öÅ©Ç÷ο츦 Æ÷ÇÔÇϸç, Á¦¾à, ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö, Áø´Ü µî ÁÖ¿ä ÃÖÁ¾»ç¿ëÀÚ ºÎ¹®ÀÇ ÀÓ»ó ÀÀ¿ëÀ» À§ÇØ Æ¯º°È÷ ¼³°èµÇ¾ú½À´Ï´Ù. ÀÌµé ºÐ¾ß¿¡¼­ NGS ±â¼úÀº ÁÖ·Î Áúº´ Áø´Ü ¹× ¸ð´ÏÅ͸µ, µ¿¹ÝÁø´Ü, ÀÓ»ó½ÃÇè, ȯÀÚ °èÃþÈ­ µî¿¡ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç(APAC), ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿, ¾ÆÇÁ¸®Ä« ¹× ³²¾Æ½Ã¾Æ(MEASA) Áö¿ªÀÇ »ç·Ê ¿¬±¸¸¦ ÅëÇØ ÀÓ»ó ÇöÀå¿¡¼­ NGS ±â¼ú »ç¿ëÀÇ ¼ºÀåÀ» ÃËÁøÇÏ°í ¾ïÁ¦ÇÏ´Â ¿äÀÎÀ» Æò°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½ÃÀå ¼öÀͰú ¿¹Ãø»Ó¸¸ ¾Æ´Ï¶ó »ê¾÷ ºÎ¹®, ±ÔÁ¦ ȯ°æ, »õ·Î¿î ºñÁî´Ï½º ¸ðµ¨À» Æò°¡ÇÏ¿© ¾÷°è°¡ Á¦½ÃÇÏ´Â ÇÙ½É ¼ºÀå ±âȸµµ ÆÄ¾ÇÇÕ´Ï´Ù.

¸ñÂ÷

»ýŰè

¼ºÀå ȯ°æ : ÀÓ»ó¿ë Â÷¼¼´ë ½ÃÄö½Ì º¯Çõ

ÀÓ»ó¿ë Â÷¼¼´ë ½ÃÄö½Ì »ýŰè

ÀÓ»ó¿ë Â÷¼¼´ë ½ÃÄö½ÌÀÇ ¼ºÀå ÃËÁø¿äÀÎ

¼ºÀå ÃËÁø¿äÀÎ : ±â±â

¼ºÀå ÃËÁø¿äÀÎ : ¿öÅ©ÇÃ·Î¿ì ¼Ö·ç¼Ç

¼ºÀå ÃËÁø¿äÀÎ : ¼­ºñ½º

¼ºÀå ÃËÁø¿äÀÎ : ÀÎÆ÷¸Åƽ½º

ÀÓ»ó¿ë Â÷¼¼´ë ½ÃÄö½Ì ºÐ¾ß ¼ºÀå ±âȸ ¿µ¿ª ºÐ¼®

ºÎ·Ï°ú ´ÙÀ½ ½ºÅÜ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Continued Investment in AI is Driving Transformational Growth by Accelerating Information Solutions Development

This Frost & Sullivan analysis examines the clinical next-generation sequencing (NGS) industry, covering the different type of products, workflows, and applications for clinical purposes. The global market is projected to grow steadily from 2024 to 2030, achieving significant revenue milestones, driven largely by services and informatics segments. The NGS market encompasses end-to-end workflows, including library preparation, sequencing, and data analysis and interpretation, specifically designed for clinical applications across key end-user segments: pharmaceutical and biotechnology, and diagnostics. Within these sectors, NGS technologies are primarily employed to diagnose and monitor diseases, as well as for companion diagnostics, clinical trials, and patient stratification.

This analysis assesses the factors driving and restraining the growth of the use of NGS technology in clinical settings and offers case studies from North America, Europe, Asia-Pacific (APAC), Latin America, and the Middle East, Africa, and South Asia (MEASA). It also identifies the core growth opportunities that the industry presents by evaluating industry segments, the regulatory environment, and emerging business models, as well as market revenue and forecasts.

Table of Contents

Ecosystem

Growth Environment: Transformation in Clinical Next-generation Sequencing

Ecosystem in Clinical Next-generation Sequencing

Growth Generator in Clinical Next-generation Sequencing

Growth GeneratorInstruments

Growth GeneratorWorkflow Solutions

Growth GeneratorServices

Growth GeneratorInformatics

Growth Opportunity Universe Analysis of the Clinical Next-generation Sequencing Sector

Appendix & Next Steps

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â